Pfizer Inc.: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Pfizer in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

• Benchmark Pfizer's performance against key rivals in the prescription pharmaceutical sector
• Assess how Pfizer's M&A driven growth strategy will impact the company's commercial performance through to 2014
• Analyze the impact of patent expiry for Pfizer's flagship product Lipitor, which accounted for c.29% of the company's prescription drug sales in 2008

• ABOUT DATAMONITOR HEALTHCARE
• About the PharmaVitae team
• Chapter 1 About this profile
  • PharmaVitae Explorer database
• Chapter structure
  • Executive summary
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors
  • Data sourcing
  • Sales data
  • Analyst consensus
• Chapter 2 Executive summary
  • Key findings
  • Prescription pharmaceutical sales and growth rate performance, 2002-14
  • Financial performance, 2002-14
  • Pfizer: PharmaVitae forecasts at a glance
  • Strategic insight
  • Acquisition of Wyeth
  • Exposure to patent expiries act as key strategic driver
  • Historical M&A activity necessitates continued acquisitions to gain scale
  • Acquisition of Wyeth will not return Pfizer to positive sales growth outlook
  • Cost cutting only route to profit growth
  • Strategic benefits of Wyeth acquisition
  • New Commercial Operating Structure
  • SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats
  • Table of figures
• Chapter 3 Quarterly news update
  • Product developments
  • Deals and alliances
  • Product deals
  • Technology deals
  • M&A activity
  • Company announcements
  • Future product milestones
• Chapter 4 Company introduction
  • Key findings
  • Background
  • Key corporate developments
  • M&A history
  • Warner-Lambert acquisition
  • Pharmacia acquisition
• Chapter 5 Company sales
  • Key findings
  • Prescription pharmaceutical sales and growth rate analysis, 2002-14
  • Product analysis
  • Product analysis, 2002-08
  • Product analysis, 2008-14
  • Therapy area analysis
  • Geographic analysis
  • Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 2008-14
  • Core analysis, 2008-14
  • Expiry analysis, 2008-14
  • Launch/core/expiry configuration, 2008-14
  • Molecule type analysis
  • Externalization analysis
• Chapter 6 Company financials
  • Key findings
  • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
  • Operating costs and profit analysis
  • Operating costs and profit analysis, 2002-08
  • Operating cost ratio and profit margin analysis, 2002-08
  • Operating cost ratio and profit margin analysis, 2008-14
  • Operating costs and profit analysis, 2008-14
• Chapter 7 Key products and competitors
  • Overview
  • Central Nervous System
  • Lyrica
  • Overview
  • Sales forecast
  • Product background & market position
  • Competitive outlook & lifecycle management
  • Chantix/Champix
  • Overview
  • Sales forecast
  • Product background/Initial market entry
  • Updated labeling request from regulatory authorities
  • Forecast outlook
  • Cardiovascular
  • Lipitor
  • Overview
  • Sales forecast
  • Product background/Market position
  • Norvasc
  • Overview
  • Sales forecast
  • Product background/Market position
  • Oncology
  • Sutent
  • Overview
  • Sales forecast
  • Product background
  • Renal Cell Carcinoma
  • NSCLC
  • Anticipated approvals in other indication settings
  • Infectious diseases
  • Zyvox
  • Overview
  • Sales forecast
  • Product background & market position
  • Vfend
  • Overview
  • Sales forecast
  • Product background & market position
  • Immunology & inflammation
  • Celebrex
  • Overview
  • Sales forecast
  • Product background & market position
  • Other
  • Xalatan/Xalacom
  • Overview
  • Sales forecast
  • Genitourinary
  • Viagra
  • Overview
  • Sales forecast
  • Product background & market position
  • Detrol/Detrol LA
  • Overview
  • Sales forecast
  • Product background & market position
• Chapter 8 Appendix
  • R&D pipeline
  • Abbreviations
  • Exchange rates
  • About Datamonitor
  • About Datamonitor Healthcare
  • Datamonitor consulting
  • Disclaimer
  • Table 1: Pfizer - PharmaVitae forecasts at a glance
  • Table 2: Pfizer key product developments, Q1 2009
  • Table 3: Pfizer product deals and alliances, Q1 2009
  • Table 4: Pfizer technology deals and alliances, Q1 2009
  • Table 5: Pfizer M&A activity, Q1 2009
  • Table 6: Pfizer company announcements, Q1 2009
  • Table 7: Pfizer future product milestones, 2009-11
  • Table 8: Pfizer product portfolio overview ($m), 2002-08
  • Table 9: Pfizer product portfolio overview ($m), 2008-14
  • Table 10: Pfizer prescription pharmaceutical sales by therapy area ($m), 2008-14
  • Table 11: Pfizer prescription pharmaceutical sales by geographic region ($m), 2008-14
  • Table 12: Pfizer launch portfolio overview ($m), 2008-14
  • Table 13: Pfizer core portfolio overview ($m), 2008-14
  • Table 14: Pfizer expiry portfolio overview ($m), 2008-14
  • Table 15: Pfizer prescription pharmaceutical sales by molecule type ($m), 2008-14
  • Table 16: Pfizer prescription pharmaceutical sales by source ($m), 2008-14
  • Table 17: Total Pfizer sales by business unit ($m), 2002-08
  • Table 18: Pfizer operating revenue/cost analysis ($m), 2002-08
  • Table 19: Pfizer operating cost ratio analysis (% of total revenues), 2002-08
  • Table 20: Pfizer operating cost ratio analysis (% of total revenues), 2008-14
  • Table 21: Pfizer operating revenue/cost analysis ($m), 2008-14
  • Table 22: Calculation of other operating expenditure for Pfizer operating revenue/cost analysis ($m), 2008-14
  • Table 23: Pfizer Key products overview
  • Table 24: Lyrica: overview
  • Table 25: Lyrica: sales forecast ($m), 2008-14
  • Table 26: Chantix/Champix: overview
  • Table 27: Chantix/Champix: sales forecast ($m), 2008-14
  • Table 28: Lipitor: overview
  • Table 29: Lipitor: sales forecast ($m), 2008-14
  • Table 30: Norvasc: overview
  • Table 31: Norvasc: sales forecast ($m), 2008-14
  • Table 32: Sutent: overview
  • Table 33: Sutent: sales forecast ($m), 2008-14
  • Table 34: Zyvox: overview
  • Table 35: Zyvox: sales forecast ($m), 2008-14
  • Table 36: Vfend: overview
  • Table 37: Vfend: sales forecast ($m), 2008-14
  • Table 38: Celebrex: overview
  • Table 39: Celebrex: sales forecast ($m), 2008-14
  • Table 40: Xalatan/Xalacom: overview
  • Table 41: Xalatan/Xalacom: sales forecast ($m), 2008-14
  • Table 42: Viagra: overview
  • Table 43: Viagra: sales forecast ($m), 2008-14
  • Table 44: Detrol/Detrol LA: overview
  • Table 45: Detrol/Detrol LA: sales forecast ($m), 2008-14
  • Table 46: Pfizer's R&D pipeline (NCEs: Phase I-registration)
  • Table 47: Exchange rates, 2009
• List of Figures
  • Figure 1: The PharmaVitae Explorer
  • Figure 2: Pfizer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
  • Figure 3: Pfizer financial performance ($m), 2002-14
  • Figure 4: Pfizer's 'growth by M&A' strategy ($m), 1999-2014
  • Figure 5: Comparison of Pfizer, Wyeth and Pfizer-Wyeth prescription pharmaceutical sales performance ($m), 2008-14
  • Figure 6: Comparison of molecule type focus for Pfizer. Wyeth and Pfizer/Wyeth (%), 2008 & 2014
  • Figure 7: Pfizer Commercial Operating Structure post-Wyeth acquisition
  • Figure 8: Pfizer SWOT analysis
  • Figure 9: Pfizer prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
  • Figure 10: Key product sales ($m), 2002-14
  • Figure 11: Pfizer key sales growth drivers and resistors ($m), 2002-08
  • Figure 12: Pfizer key sales growth drivers and resistors ($m), 2008-14
  • Figure 13: Pfizer prescription pharmaceutical sales by therapy area ($m), 2002-14
  • Figure 14: Pfizer prescription pharmaceutical sales by geographic region ($m), 2002-14
  • Figure 15: Pfizer launch/core/expiry configuration ($m), 2008-14
  • Figure 16: Pfizer prescription pharmaceutical sales by molecule type ($m), 2002-14
  • Figure 17: Pfizer prescription pharmaceutical sales by source ($m), 2002-14
  • Figure 18: Pfizer operating revenue/cost analysis ($m), 2002-14
  • Figure 19: Global sales of Neurontin & Lyrica ($m), 2001-14
  • Figure 20: Geographic breakdown of Chantix/Champix revenues ($m), 2006-14
  • Figure 21: Share of global statin market by leading brand, 2001-14 (US$m)